Breckenridge Pharmaceutical, Inc.
Breckenridge Pharmaceutical Settles 'Paragraph IV' Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
Published in Drug Law Weekly, January 22nd, 2008
Breckenridge enjoys a shared 180-day exclusivity period and will immediately launch Oxcarbazepine Tablets 150 mg, 300 mg, and 600 mg. Oxcarbazepine Tablets are AB rated to Trileptal(R), a $600 million brand name drug marketed by Novartis Pharmaceuticals Corporation, and are used in treating seizures.
Breckenridge is actively...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2008-01-22)
More Articles from Drug Law Weekly
- Adams Respiratory Therapeutics, Inc.
Reckitt Benckiser Receives Hart-Scott-Rodino Antitrust Clearance for Acquisition of Adams Respiratory Therapeutics - American Association for Justice
Statement from AAJ President Kathleen Flynn Peterson on ATRA's Latest Attack on Civil Justice Attorneys - Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering - Behavior
New behavior study findings have been reported by M.A. Salinger and co-researchers - Biotech Business
2008 Brings New FDA Post-Market Requirements That Demand Expert Services, Reports Watermark Research Partners - Cancer
Federal Government Receives Failing Grades on Tobacco Control in Annual American Lung Association Report - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
